← REGULATORY CHANGES
FEDERAL REGISTER · RULESeptember 16, 2024IN FORCE

Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Clozapine Test System

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSIN FORCE
EFFECTIVESep 16, 2024
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGDevice
Document type
Rule
Agency
Health and Human Services Department
Published
September 16, 2024
Effective
September 16, 2024
Document number
2024-20895
CFR references
21 CFR 862
Docket
FDA-2024-N-4058
ABSTRACT

The Food and Drug Administration (FDA, Agency, or we) is classifying the clozapine test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the clozapine test system's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices.

Abstract as published in the Federal Register.